Epizyme's shares fall after receiving new FDA approval for cancer drug [MarketWatch]
Epizyme, Inc. (EPZM)
Last epizyme, inc. earnings: 2/24 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
epizyme.com
Company Research
Source: MarketWatch
Shares of Epizyme Inc. were down 2.3% in premarket trading on Friday, the day after it said the Food and Drug Administration had approved Tazverik as a treatment for relapsed or refractory follicular lymphoma. Tazverik was first approved by the FDA in January, to treat epithelioid sarcoma. "In our view, there remains no clear standard of care in the relapsed and/or refractory FL population as not all patients benefit from today's available therapies," Dr. Shefali Agarwal, Epizyme's chief medical officer of Epizyme, said in a news release. The monthly list price is $15,500 for all approved indications, a spokesperson for the company said in an email. However, the labels for the two new indications are narrower than some analysts had expected. "We believe this label may disappoint some investors who had expected a broad, biomarker agnostic label in the 3L setting," SVB Leerink's Andrew Berens wrote in a note. Other analysts see a rosier future for the drug, with Wedbush analysts saying
Show less
Read more
Impact Snapshot
Event Time:
EPZM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPZM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPZM alerts
High impacting Epizyme, Inc. news events
Weekly update
A roundup of the hottest topics